Ann-Christin Mörk
Research Subjects
Ann-Christin Mörk has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Dennis A. Revicki
United BioSource Corporation
1 shared publication - Elisabeth Ståhl
AstraZeneca R&D, Lund, Sweden
1 shared publication - Elizabeth F. Juniper
Dept of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada
1 shared publication - Emuella M Flood
Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, United States, London, UK
1 shared publication - Erwin De Cock
United BioSource Corporation, Barcelona, Spain
1 shared publication - Klas Svensson
AstraZeneca R&D, Lund, Sweden
1 shared publication
Latest Publications
- Open Access
- 15 August 2006
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 4 (1) , 1-51
Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries
Background: The Asthma Symptom Utility Index (ASUI) is a preference-based outcome measure used in US clinical trials and cost-effectiveness studies for asthma. This study evaluated ASUI preference weights in Europe to determine whether the multi-attribute utility function, based on preferences from a US population, is generalizable across countries. Methods: Data were collected from ninety asthma patients from Italy, France, and the United Kingdom using the Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire, and the ASUI. Subjects rated their preferences for 10 asthma health states using a visual analogue scale (VAS) and a standard gamble (SG) interview. Results: All multi-symptom states showed statistically significant differences (p < 0.001) between countries in mean VAS scores. Mean SG utility scores between the US and France and the US and Italy demonstrated statistically significant differences (p < 0.001) for three states: severe wheeze; moderate cough and wheeze; and moderate cough and dyspnea. Because of these differences, the multi-attribute utility functions derived within countries were somewhat different. Despite these differences, country-specific algorithms captured a similar rank ordering of patients by disease severity, were strongly correlated (r = 0.971 to 0.995), and demonstrated similar relationships with symptom and AQLQ scores. Conclusion: Results of this study suggest that the ASUI may be a complementary patient-reported outcome for clinical studies and may be useful for applications in cost-effectiveness studies comparing different asthma treatments.
- 15 August 2006
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 4 (1) , 1-51
Open AccessEvaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries
Background: The Asthma Symptom Utility Index (ASUI) is a preference-based outcome measure used in US clinical trials and cost-effectiveness studies for asthma. This study evaluated ASUI preference weights in Europe to determine whether the multi-attribute utility function, based on preferences from a US population, is generalizable across countries. Methods: Data were collected from ninety asthma patients from Italy, France, and the United Kingdom using the Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire, and the ASUI. Subjects rated their preferences for 10 asthma health states using a visual analogue scale (VAS) and a standard gamble (SG) interview. Results: All multi-symptom states showed statistically significant differences (p < 0.001) between countries in mean VAS scores. Mean SG utility scores between the US and France and the US and Italy demonstrated statistically significant differences (p < 0.001) for three states: severe wheeze; moderate cough and wheeze; and moderate cough and dyspnea. Because of these differences, the multi-attribute utility functions derived within countries were somewhat different. Despite these differences, country-specific algorithms captured a similar rank ordering of patients by disease severity, were strongly correlated (r = 0.971 to 0.995), and demonstrated similar relationships with symptom and AQLQ scores. Conclusion: Results of this study suggest that the ASUI may be a complementary patient-reported outcome for clinical studies and may be useful for applications in cost-effectiveness studies comparing different asthma treatments.
- Open Access
- 16 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-58
Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older
Background: The age limit for some adult asthma clinical trials has recently been lowered to 12 years. In this study we have made minor modifications to the standardised version of the adult Asthma Quality of Life Questionnaire (AQLQ(S)) to make it valid for patients 12 years and older (AQLQ12+).Methods: We have used two clinical trial databases, in which the AQLQ12+ was used, to compare the measurement properties of the questionnaire in patients 12–17 years and patients 18 years and older. A total of 2433 patients (12–75 years), with current asthma and with data that could be evaluated both at randomisation and end of treatment, were included.Results: The analysis showed that internal consistency, responsiveness and correlations with other clinical indices were very similar in patients 12–17 years and patients 18 years and older.Conclusion: The measurement properties of the AQLQ12+ are similar in adolescents and adults and therefore the instrument is valid for use in adult studies which include children 12 years and older.
- 16 September 2005
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 3 (1) , 1-58
Open AccessModification of the asthma quality of life questionnaire (standardised) for patients 12 years and older
Background: The age limit for some adult asthma clinical trials has recently been lowered to 12 years. In this study we have made minor modifications to the standardised version of the adult Asthma Quality of Life Questionnaire (AQLQ(S)) to make it valid for patients 12 years and older (AQLQ12+).Methods: We have used two clinical trial databases, in which the AQLQ12+ was used, to compare the measurement properties of the questionnaire in patients 12–17 years and patients 18 years and older. A total of 2433 patients (12–75 years), with current asthma and with data that could be evaluated both at randomisation and end of treatment, were included.Results: The analysis showed that internal consistency, responsiveness and correlations with other clinical indices were very similar in patients 12–17 years and patients 18 years and older.Conclusion: The measurement properties of the AQLQ12+ are similar in adolescents and adults and therefore the instrument is valid for use in adult studies which include children 12 years and older.